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.P.J. Senaratne, 
.___._._ , 
of Cardiology, Univ. of Alberta, Edmonton, Canada. 
Cough is an adverse effect of angiotensin converting 
enzyme (ACE) inhibitors and is believed to be secondary 
to the effect of ACE inhibitors on bradykinin (B) 
breakdown. The purpose of the present study was to 
identify a potential wagal sensory mechanSsm for this 
cough response. The rapidly adapting receptors (RAR) of 
the airways are activated by changes in extra-vascular 
luna wa;er. Since B is an inflammatory mediator which 
in&eases vascular permeability, experiments were 
aerformed in anesthetized, artificially ventilated and 
W t 
tis of covarfance, en$ 
from before E (pt0.01). . 
RAR are stimulated by B and this effect is enhanced by 
E. It is concluded that the cough observed after 
administration f E is due to stimulatfon of RAR. 
THE MESSENGER RNA FOR THE L~L-RECEPTg~ IS INCR Y 
VERAPAMIL 
Helmut G Eckardt, M.D., Merck Sharp 5 Dohme, Munich 
To see if the Ca’+entry blocker induced stimulation of 
LDL-receptor synthusis is correlated with a selective 
increase in the amount of LDL-receptor specific Mona 
human skin fibroblasts were incubated in the absence 
or presence of Verapemil. Trifluoperezine, which we 
recently had shown to increase LDL-receptor mRNA and 
25Hydroxycholesterol, which is known to supress the 
synthesis of LDL-receptor were use 
trol. RN4 was subjected to Norther 
was probed sequentially with 32&l 
cDNA and R-ectin pseudogene 3NA fragments. 
terion of 3ize corre 
The intensities of the hyb 
that RNA isolated fr 
contained more LDL-receptor mRNA than did RNA i 
from control cells. 
P-fold and the pretr 
effect. The maximum 
4 hours of preincuba 
The present data show that the verepamil induced in- 
crease in LBL-receptor ectivity is correlated with a 
corresponding increase in LDL receptor mRNA. These re- 
sults indicate that verapamil se1 ctively enhance the 
amount of LDL-receptor in culture human fibroblasts. 
INHIBITION OF AT~E~~SC~BBOSIS 
BITS 
BY IN 
Richard E. sievers, B.S., 
g, Ph.D., William W. Parmley, 
University of Californi SatI M.D., F.A.C.C. ; 
To evaluate the effects of Lovastatin on 
cholesterol-induced atherosclerosis, 50 Ned 
Zealand rabbits in five groups were fed a 0.3% 
cholesterol diet for 10 weeks. Groups L10 and 
LZO received 10 and 20 mg/day of Lovastatin 
respectively. The % endothelial surface covered 
with lipid lesions was determined by planimetry. 
% Lesions Contra? LlO L20 
Aorta 25+16 8+7** 9+4* 
Pul. Art. 24716 10;6* 4:r;5** 
* Significantly diTferent from c&trol groujj. 
No statistical differences were found in the 
bleeding time. Groups LlO and L20 had lower 
levels of serum cholesterol and LDL-cholesterol 
than those in the control group (715, 832 **s 
879; 681, 7% vb 846 mg/dl) et 10 weeks. 
Another control group had a high lipid diet for 
10 weeks and a normal diet for 10 weeks. .1 
treatment group had the same diet sequence, but 
also had 20 mg/day of Lovastatin the last IL0 
weeks. No regression of atherosclerosis was 
seen in the treatment group. 
This study shows that Lovastatin ca 
the development of aortic and pulmonary 
atherosclerosis in cholesterol-fed rabbits, 
did not regress established atherosclerosis. 
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